A previous retrospective study [23] reported that the duration of therapy for somnolentia, NSAID prescription, age, maintenance dose for ataxia, serum creatinine level for body weight gain, neurotrophin use, and serum creatinine level for edema, which may go unrecognized and lead to the loss of mobility and prolonged hospitalization [24], were risk factors for PGB-related adverse events. The gene discussed is BDNF; the disease is Ataxia.